



Digestive Diseases Research Seminar
Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases

YaleCME
CONTINUING MEDICAL EDUCATION

ITPR3: Channeling calcium into liver carcinogenesis

Mateus T. Guerra, PhD

Research Scientist, Department of Medicine
Yale School of Medicine

Tuesday, September 15, 2020

5:00 - 6:00 pm

<https://zoom.us/j/97397924656?pwd=Q3NzRHFlMHVrOER0bzdTc2FPU1I4QT09>

Host: Yasuko Iwakiri, PhD

To record your attendance to this activity, text the Activity Code (20522) for your RSS activity to 203-442-9435. You will receive a message back that verifies your activity attendance has been recorded for CME credit.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, and staff, and local GI physicians. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Hepatocellular carcinoma (HCC) is the fourth deadliest cancer worldwide¹ and the current pharmacological standard of care (sorafenib) has only a mild survival benefit over placebo². There is a clear need for novel and more effective pharmacological therapies for HCC. In this lecture, we will explore the role played by inositol 1, 4, 5 trisphosphate receptors (ITPRs) in the development of HCC and how controlling its expression might open new therapeutic avenues for the treatment of liver cancer³. **References:** 1. Yang, J.D. et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nature reviews. Gastroenterology & hepatology* 16, 589-604 (2019); 2. Llovet, J.M. et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 359, 378-390 (2008); 3. Guerra, M.T. et al. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. *Gut* 68, 1676-1687 (2019). **Objectives:** Understand the basic molecular components responsible for Calcium signaling in hepatocytes; Explore how intracellular Ca²⁺ channels (InsP3 receptors) might regulate liver cell growth and cell death; Outline the molecular mechanisms controlling InsP3R in the liver in health and disease and how these might be explored for the treatment of hepatocellular carcinoma. **Faculty Disclosures:** M Guerra - None; Iwakiri - None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**